Disitamab vedotin

Grace Liu from Sino Biological discusses Antibody-Drug Conjugates (ADCs), a cancer therapy combining precision targeting with potent cytotoxic drugs. ADCs consist of a monoclonal antibody, cytotoxic payload, and linker, balancing efficacy and safety. Sino Biological offers comprehensive ADC development solutions, aiding in the complex process from discovery to clinical studies.

On Dec 12, 2024, RemeGen presented phase III study data of Disitamab Vedotin (DV) for HER2-positive advanced breast cancer with liver metastasis at the 47th SABCS. This is the first global prospective randomized phase III study on a HER2-targeting ADC showing significant efficacy.

RemeGen presented phase III study data on Disitamab Vedotin (DV) for HER2-positive advanced breast cancer with liver metastasis at SABCS, showing significant PFS improvement over Lapatinib plus Capecitabine. DV demonstrated a manageable safety profile and potential as a new treatment option.

RemeGen presented phase III study data on Disitamab Vedotin (DV) for HER2-positive advanced breast cancer with liver metastasis at the 47th SABCS. DV showed significant improvement in progression-free survival compared to Lapatinib plus Capecitabine, with a manageable safety profile. The study is the first global phase III on a HER2-targeting ADC for this patient group.

RemeGen presented phase III study data of Disitamab Vedotin (DV) at SABCS, showing significant efficacy in HER2-positive advanced breast cancer with liver metastasis. DV improved progression-free survival vs. Lapatinib plus Capecitabine, with a manageable safety profile. BLA for DV accepted by China's CDE in Oct 2024.

Disitamab vedotin (RC48) showed efficacy with manageable safety in HER2-positive and HER2-low metastatic breast cancer with PAM pathway activation, with ORR of 34.40% and DCR of 81.97% in all patients. No significant PFS difference was observed between HER2-positive and HER2-low subgroups.

Dr. Jacqueline Brown discussed emerging perioperative systemic therapies for muscle invasive bladder cancer at the 2024 SUO annual meeting, highlighting the VESPER trial showing dose dense MVAC improved survival over gemcitabine + cisplatin, and the CheckMate 274 trial demonstrating adjuvant nivolumab's efficacy. Ongoing trials like NIAGARA and ENERGIZE explore chemo-immunotherapy combinations, while novel agents such as enfortumab vedotin and sacituzumab govitecan show promise in the perioperative setting.

Emerging therapies for bladder cancer include erdafitinib, enfortumab vedotin, and pembrolizumab. Key studies highlight genomic heterogeneity, biomarker guidance, and immunotherapy responses. Precision oncology faces challenges with clonal evolution and resistance mechanisms. Future directions focus on improving biomarker-driven trials and understanding tumor immune microenvironments.

Endometrial cancer cases in the U.S. have risen, particularly in non-endometrioid subtypes, with unclear reasons but obesity suspected. Research funding has declined, yet new drug developments offer hope. Dana-Farber researchers focus on hormonal, immunotherapy, antibody-drug conjugates, and replication stress to improve patient outcomes.